

Beat: Health

3D PRINTED PILL APPROVED BY FDA FOR EPILEPSY IN USA

EXPECTED TO HIT MARKET IN 2016

PARIS - LOS ANGELES, 09.08.2015, 13:50 Time

USPA NEWS - The drug is called SPRITAM and is designed to treat seizures in people suffering from epilepsy. It is a new version of a seizure medication that has been on the market for years. The FDA has previously approved medical devices that have been 3D printed...

The Company Aprecia Pharmaceuticals (behind the Spritam pill) has said that it planned to develop other medications using its 3D platform. The prescription tablet was approved for internal human consumption. Previous tablets did not dissolve easily. Seizure medication is often large and difficult to swallow, particularly for the elderly and children. So, it is fitted for the patients who struggle with current medication experience.

Printing the drugs allows layers of medication to be packaged more tightly in precise dosages. A separate technology developed by the firm, known as ZipDoze, makes high-dose medications easier to swallow. Printing the drug meant it could package up to 1,000 milligrams into individual tablets.

Being able to 3D print a tablet offers the potential to create bespoke drugs based on the specific needs of patients, rather than having a one product fitting all approach, according to experts. The pill is the latest of a series of healthcare products that utilize 3D printing, including jaw replicas, dental implants and hip replacements. Scientists are also developing 3D printed tracheas, bones, ears, kidneys and skins.

Article online:

<https://www.uspa24.com/bericht-4806/3d-printed-pill-approved-by-fda-for-epilepsy-in-usa.html>

Editorial office and responsibility:

V.i.S.d.P. & Sect. 6 MDSStV (German Interstate Media Services Agreement): Ruby BIRD (Journalist/Director/Photographer)

Exemption from liability:

The publisher shall assume no liability for the accuracy or completeness of the published report and is merely providing space for the submission of and access to third-party content. Liability for the content of a report lies solely with the author of such report. Ruby BIRD (Journalist/Director/Photographer)

Editorial program service of General News Agency:

UPA United Press Agency LTD
483 Green Lanes
UK, London N13NV 4BS
contact (at) unitedpressagency.com
Official Federal Reg. No. 7442619